29,500 results
upgraded shares of Eli Lilly and (NASDAQ:LLY) from an underperform rating to a hold rating in a research note issued to investors on Monday, American Banking News.com reports. The firm currently has $54.00 price target on the stock, up from their …Zolmax News · 4/15/2014
Stock analysts at Jefferies Group upped their price objective on shares of Eli Lilly and (NYSE:LLY) to $54.00 in a report issued on Monday, American Banking and Market News reports. The firm currently has a “hold” …wkrb13.com · 4/14/2014
In-depth coverageThe firm currently has a $54.00 price target on the stock, up from their previous price target of $45.00. Jefferies Group’s price target points to a potential downside of 9.11% from the company’s current price. Eli Lilly and (NYSE:LLY) traded up 0.67% ...Zolmax News · 1 day ago
More from Bing News
Eli Lilly and (NASDAQ:LLY) was upgraded by Jefferies from an “underperform” rating to a “hold” rating in a research note issued on Monday, Stock Ratings News reports. The firm currently has a $54.00 price …wkrb13.com · 4/14/2014
Though there is a tough competition expected to happen with Novartis AG (ADR) (NYSE:NVS) and Eli Lilly and Co (NYSE:LLY) also entering into the business ... is following the stock looks as a good investment for a long term.NYSE Post · 4/11/2014
Eli Lilly carries a Zacks Rank #3 (Hold). A better-ranked stock in the pharma sector is Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), carrying a Zacks Rank #1 (Strong Buy). LILLY ELI & CO (NYSE: LLY): Free Stock Analysis ReportBenzinga · 1 day ago
After a long court battle for Eli Lilly (NYSE: LLY ) and partner Takeda ... after the amounts have been significantly reduced through the appeals process. 6 stock picks poised for incredible growth They said it couldn't be done. But David Gardner has ...The Motley Fool · ByDavid Williamson andMichael Douglass · 4/15/2014
Eli Lilly (LLY) focuses on innovation and meeting medical needs in the ... Both of these points do not help Eli Lilly's argument for the intrinsic value of the stock. Worldwide revenue decreased by 7% due to the loss of exclusivity for Zyprexa.Seeking Alpha · 4/15/2014
from an “underperform” rating to a “hold” rating in a research report issued on Monday, StockRatingsNetwork reports. The firm currently has a $54.00 price objective on the stock, up from their previous price objective of $45.00. Jefferies ‘s ...Ticker Report · 4/14/2014
- © 2014 Microsoft |
- Privacy and Cookies |
- Legal |
- Advertise |
- About our ads |
- Help |
- Feedback